UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000038870
Receipt number R000044328
Scientific Title A study to evaluate the effect of plant-derived ingredients on TTR stability -Exploratory study-
Date of disclosure of the study information 2020/12/15
Last modified on 2020/05/20 12:44:48

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

A study to evaluate the effect of plant-derived ingredients on TTR stability -Exploratory study-

Acronym

An exploratory study to evaluate the effect of plant-derived ingredients on TTR stability

Scientific Title

A study to evaluate the effect of plant-derived ingredients on TTR stability -Exploratory study-

Scientific Title:Acronym

An exploratory study to evaluate the effect of plant-derived ingredients on TTR stability

Region

Japan


Condition

Condition

None

Classification by specialty

Not applicable Adult

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

Exploratory verification of transthyretin (TTR) stability in the plasma from healthy Japanese who have taken plant-derived ingredients (300 mg / day, 12 weeks intakes)

Basic objectives2

Others

Basic objectives -Others

Verification of the effect of plant-derived ingredients on TTR stability in plasma

Trial characteristics_1

Exploratory

Trial characteristics_2

Others

Developmental phase

Not applicable


Assessment

Primary outcomes

TTR stability

Key secondary outcomes

None


Base

Study type

Others,meta-analysis etc


Study design

Basic design


Randomization


Randomization unit


Blinding


Control


Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms


Purpose of intervention


Type of intervention


Interventions/Control_1


Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

35 years-old <

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

1) Japanese healty females and males older than 35 years
2) Subjects with stable plasma concentrations of the plant-derived ingredients quantitated at 4, 8, and 12 weeks of intakes
3) Subjects with the high averaged concentration of the plant-derived ingredients quantitated at 4, 8, and 12 weeks of intakes
4) Subjects who agreed in writing prior to the start of the trial with sufficient understanding of the purpose and contents of this study

Key exclusion criteria

1) Subjects judged as unsuitable for this study by the principal investigator

Target sample size

10


Research contact person

Name of lead principal investigator

1st name Iwao
Middle name
Last name Funahashi

Organization

KANEKA CORPORATION

Division name

Pharma & Supplemental Nutrition Solutions Vehicle

Zip code

107-6028

Address

1-12-32, Akasaka, Minato-ku, Tokyo, Japan

TEL

050-3133-6397

Email

Iwao.Funahashi@kaneka.co.jp


Public contact

Name of contact person

1st name Soichi
Middle name
Last name Yoneda

Organization

APO PLUS STATION CO., LTD.

Division name

CRO Department Food Test Division

Zip code

103-0027

Address

2-14-1, Nihonbashi, Chuo-ku, Tokyo,

TEL

03-6386-8809

Homepage URL


Email

s-yoneda@apoplus.co.jp


Sponsor or person

Institute

APO PLUS STATION CO., LTD.

Institute

Department

Personal name



Funding Source

Organization

KANEKA CORPORATION

Organization

Division

Category of Funding Organization

Profit organization

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Institutional Review Board,Kanazawabunko Hospital

Address

Kanagawa Prefecture Yokohama City Kanazawa-ku Kaburiya Higashi 2-chome 6-22

Tel

045-785-3311

Email

watanabe@kanabun-hp.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions

金内メディカルクリニック(東京都)、上尾中央第二病院(埼玉県)、笛吹中央病院(山梨県)、武蔵境クリニック(東京都)、久野マインズタワークリニック(東京都)


Other administrative information

Date of disclosure of the study information

2020 Year 12 Month 15 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled

10

Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2019 Year 12 Month 11 Day

Date of IRB

2019 Year 12 Month 18 Day

Anticipated trial start date

2019 Year 12 Month 19 Day

Last follow-up date

2020 Year 05 Month 31 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information

None


Management information

Registered date

2019 Year 12 Month 13 Day

Last modified on

2020 Year 05 Month 20 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000044328


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name